This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Cornell University, Temple University. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2021
Title: Madesh Muniswamy: Innovator in Calcium Transport Inhibition
Introduction
Madesh Muniswamy is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of biochemistry, particularly in the development of methods for treating diseases related to calcium transport.
Latest Patents
Madesh holds a patent for "Ruthenium μ-nitrido complexes and their use as calcium uptake inhibitors." This innovative method focuses on treating or preventing diseases by regulating calcium transport through the mitochondrial calcium uniporter (MCU). The patent outlines a method that involves administering a therapeutically effective amount of an MCU inhibitor with a specific chemical structure, which includes various groups such as halides, amines, and phosphines.
Career Highlights
Throughout his career, Madesh has worked at prestigious institutions, including Cornell University and Temple University. His research has contributed to advancements in understanding calcium transport mechanisms and their implications in various medical conditions.
Collaborations
Madesh has collaborated with notable colleagues, including Justin Wilson and Sarah Nathan. Their combined expertise has furthered research in the field of calcium transport and its therapeutic applications.
Conclusion
Madesh Muniswamy's innovative work in calcium transport inhibition highlights his role as a significant contributor to biochemistry. His patent and collaborations reflect his commitment to advancing medical science and improving treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile